New results confirm that the drug, Balversa (erdafitinib), can benefit people whose tumors have a certain genetic alteration.

The cancer is particularly difficult to treat with traditional therapies.

“The bladder cancer research community pulled together to get this trial done,” says principal investigator Thomas Flaig, MD.

More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.

HIV-positive individuals are also diagnosed with cancer at later stages than those without the virus.

Balversa led to tumor regression in about a third of patients with susceptible genetic mutations.

Here’s a list of the approved drugs to treat bladder cancer. Click on any of the medications for more info on indications, dosing and...